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Abstract To examine the association of 1) race/ethnicity
and 2) numeracy with awareness of DTC genetic tests.
Secondary analysis of 6,754 Hispanic, black, and white
adult respondents to the National Cancer Institute’s 2007
Health Information National Trends Survey (HINTS). Lo-
gistic regression was used to examine sociodemographic
predictors of DTC genetic tests awareness including race/
ethnicity, income, education, and gender. Next, two nu-
meracy variables were added to the model. After control-
ling for sociodemographic variables, black respondents
were significantly less likely to have heard of DTC ge-
netic tests compared to white respondents (OR00.79; CI:
0.65–0.97). When numeracy variables were added to the
model, the effect of black race was no longer significant
(OR00.84; CI: 0.69–1.04). Hispanic respondents did not
significantly differ from white respondents in awareness of
DTC genetic tests. Other significant correlates of DTC
genetic tests awareness in the full model included educa-
tion, income, age, and numeracy variables including de-
gree to which people use medical statistics and numbers
to make health decisions, and preference for words or
numbers when discussing “the chance of something
happening.” Although black respondents were generally
less aware of DTC genetic tests than white respondents,
this relationship appears to be partially mediated by
numeracy.
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Introduction
The number of genetic tests, including direct-to-consumer
products, has grown tremendously in the past two decades,
from approximately 100 in the early 1990’s to more than
1,000 in 2011 (Genetics and Public Policy Center 2006;
McBride et al. 2010). Direct-to-consumer (DTC) genetic
tests are those marketed directly to consumers via television,
print advertisements, or the Internet. They allow a person to
obtain genetic information without involving a doctor or
insurance company in the process and provide an estimate
of an individual’s statistical risk for developing a specific
health condition (Genetics Home Reference 2011). Major
categories of DTC genetic tests include: 1) health-related
tests to determine risk for developing specific diseases, 2)
nutrigenomic tests to develop individualized diet plans,
and 3) non-medical tests that scan the genome for variants
related to different aspects of life such as ancestry or
personality (National Human Genome Research Institute
2010b). There is ongoing debate about the widespread
availability and appropriate regulation of DTC genetic
tests (Kutz 2010; Hogarth et al. 2008). Currently, the Food
and Drug Administration has oversight of DTC genetic
tests and products, while the Federal Trade Commission
regulates advertising (National Human Genome Research
Institute 2010a).
In 2002, Myriad Genetics launched the first major DTC
publicity campaign for its BRCA1/BRCA2 tests for risk of
hereditary breast and ovarian cancer syndromes (McBride et
al. 2010). Five years later, companies including 23 and Me,
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deCODE Genetics, Navigenics, and Knome started offering
DTC genetic tests for various health conditions, as well as
complete genome sequencing (McBride et al. 2010). Sup-
porters of DTC genetic tests advocate that consumers have a
right to obtain their genetic information without approval or
interference from physicians or insurance companies
(Hogarth et al. 2008; 23andMe 2011). Those against these
tests argue that they can be misleading, poorly regulated,
and lacking sufficient involvement of genetics service pro-
viders (Gollust et al. 2002; Matloff and Caplan 2008;
McGuire and Burke 2008; Kutz 2010). A growing number
of professional groups have issued position statements and
guidelines about DTC genetic tests (American College of
Medical Genetics 2008; American Society of Human
Genetics 2007; National Society of Genetic Counselors
2007; Ameer and Krivoy 2009). For example, the American
College of Medical Genetics suggests the following require-
ments for all DTC genetic testing protocols: 1) a knowl-
edgeable professional be involved in the ordering and
interpretation of DTC genetic tests; 2) consumers under-
stand the limitations of what such tests can or cannot say
about health; 3) scientific evidence about the test is clearly
stated; 4) the clinical testing laboratory is accredited by a
reputable organization; and 5) individual privacy concerns
be addressed (American College of Medical Genetics 2008).
Previous studies have evaluated racial and ethnic differ-
ences in attitudes, knowledge, and preferences for both DTC
and clinical genetic tests, yet the results have been mixed
(Laskey et al. 2003; Hipps et al. 2003; Suther and Kiros
2009). Goddard et el evaluated public awareness and use of
DTC nutrigenomic tests using the Behavioral Risk Factor
Surveillance System (BRFSS) and found that race/ethnicity
was not associated with awareness (Goddard et al. 2009).
Regarding clinical genetic tests, Armstrong et al found that
African American women with a history of breast or ovarian
cancers were less likely than white women to seek out
BRCA1/BRCA2 testing and counseling within an insured
population (Armstrong et al. 2005). Singer et al also
assessed preferences for clinical prenatal testing among
African American, Latino, and White respondents using
hypothetical scenarios with wording variations for males
and females. They found that Latinos and African Ameri-
cans were more likely than whites respondents to prefer
clinical prenatal and adult genetic tests (Singer et al. 2004).
While the literature on numeracy and health is growing
(Powers et al. 2010; Peters et al. 2007), there is a paucity of
data on racial/ethnic disparities in numeracy. Disparities in
numeracy have been shown among emergency department
patients, diabetics, and people living with HIV (Waldrop-
Valverde et al. 2010; Osborn et al. 2009; Ginde et al. 2008).
In cross-sectional surveys conducted with patients in emer-
gency departments, Ginde et al found that, compared to
white, Hispanic and black race were associated with lower
numeracy after controlling for other demographic variables
(Ginde et al. 2008). In another cross-sectional study of adult
patients with type 2 diabetes, Osborn et al showed that
African American race was associated with lower diabetes
related numeracy (Osborn et al. 2009). Finally, in a sample
of HIV positive African American, Hispanic, and white
patients, Waldrop-Valverde et al found that medication man-
agement among African Americans was mediated by low
numeracy (Waldrop-Valverde et al. 2010).
To date, few studies have evaluated the relationship be-
tween numeracy and genetic tests (DTC and clinical includ-
ed). Genetic tests estimate an individual’s statistical risk for
developing a health condition. Since test results can be
reported in a variety of ways including relative risk ratios,
rates, and probabilities, some quantitative ability and com-
fort with numbers is needed (Leighton et al. 2011). Specif-
ically, a person must have the ability to comprehend, use,
and assign meaning to numbers (Reyna et al. 2009). This
concept is broadly defined as numeracy. However, it should
be noted that there are several definitions of numeracy in the
literature.
A recent study by Leighton et al evaluated the public’s
understanding and ability to interpret DTC genetic test
results compared to genetic counselors (2011). Both groups
were provided with hypothetical sample test results explain-
ing the risk of developing a health condition. Though nu-
meracy was not measured directly in the study, the authors
found that the public was significantly more likely than
genetic counselors to misinterpret the meaning of results
and to overestimate the usefulness of results for future
medical care.
The objectives of our study are to examine the associa-
tion of race/ethnicity on DTC genetic tests awareness and to
evaluate the role that numeracy may play in this relationship
within the 2007 Health Information National Trends Survey
(HINTS). In this study, we explore how race/ethnicity and
numeracy may interact to create a person’s tendency to
avoid or seek out DTC genetic tests, as well as their confi-
dence and ability to use results to make health decisions. A
better understanding of the relationships between these var-
iables may inform how personal genomic service providers
and healthcare professionals should communicate the bene-
fits, limitations, and meaning of such tests.
Methods
HINTS Public Use Data Set
The Health Information National Trends Survey (HINTS) is
a biennial, cross-sectional survey of American adults funded
by the National Cancer Institute. HINTS collects nationally
representative data about the public’s use of general health
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and more specifically, cancer-related information. It assesses
how people access and use health information, how people
use information technology to manage their health and
health information, and how people report engaging in
healthy behaviors. The survey was conducted in 2003,
2005, and 2007. Our analyses use 2007 data, the first year
DTC genetic tests awareness was assessed (National Cancer
Institute 2009b).
Participants
A total of 7,674 individuals participated in the 2007 HINTS.
For our analyses, we limited the sample to the 6,754 indi-
viduals who self-identified as being non-Hispanic Black/
African American, non-Hispanic White, or Hispanic/Latino.
Due to small sample sizes, those who self-identified as
Asian, American Indian or Alaskan Native, Native Hawaiian
or Pacific Islander, or multiracial were excluded. Our
subsample of non-Hispanic Black/African American,
non-Hispanic White or Hispanic/Latino comprised 94%
of the full data set.
Procedures
The sample design for HINTS 2007 consisted of two sam-
ples with each sample selected from a separate frame. One
sample was drawn as a Random Digit Dial telephone survey,
using a Computer Assisted Telephone Interview (CATI)
format. Survey administration averaged 30 minutes per re-
spondent. The second national random sample was selected
from a list of addresses from the United States Postal Ser-
vice administrative records. All adults at each sampled
address are asked to fill out the questionnaire and return it
in a postage-paid envelope (National Cancer Institute
2009b). Approximately 3,582 surveys were completed by
mail and 4,092 were completed via telephone (National
Cancer Institute 2009b). Additional details about the study
procedures and measures can be found elsewhere (National
Cancer Institute 2009a).
Measures
DTC genetic tests awareness was the dependent variable.
Participants were asked, “Genetic tests that analyze your
DNA, diet, and lifestyle for potential health risks are cur-
rently being marketed by companies directly to consumers.
Have you heard or read about these genetic tests?” Re-
sponse options were yes and no. Sociodemographic varia-
bles included in the analyses were race/ethnicity, gender,
age, education, and income.
Respondents were asked to rate numeracy variables using
a Likert-type scale with various response options. The first
question was, “In general, how easy or hard do you find it to
understand medical statistics?” Response options included
very easy, easy, hard, or very hard. The second question
was, “In general, I depend on numbers and statistics to help
me make decisions about my health.” Response options
were strongly agree, agree, disagree, or strongly disagree.
The third question was, “People can talk about the chance
of something happening using either words, like “it rarely
happens” or numbers, like “there’s a 5% chance.” When
people tell you the chance of something happening do you
prefer they use words or numbers? Response options were
generally prefer words, generally prefer numbers, or no
preference. These three numeracy questions were asked in
both the mail and telephone survey, and thus included in the
analysis.
Numeracy variables were treated separately because they
measure different aspects of numeracy. For example, the
question about understanding medical statistics being easy
or hard can be considered a general measure of subjective
ability (Woloshin et al. 2005). Dependence on numbers and
medical statistics to make health decisions may reflect one’s
confidence in using numeracy information. Furthermore, the
tendency to favor numbers or words when discussing “the
chance of something happening” reflects one’s subjective
numeracy preference (Fagerlin et al. 2007): that is, prefer-
ence for numbers as opposed to facility with them. Pearson
correlations for the three numeracy variables were evaluated
and did not exceed 0.22.
Data Analysis
Two logistic regression models were used in this study. The
initial model examined the relationship between race/ethnic-
ity (categorized as white, black, and Hispanic) and DTC
genetic tests awareness controlling for sociodemographic
variables. The second model added numeracy variables to
assess how much, if at all, numeracy mediated the racial/
ethnic disparities in DTC genetic tests awareness. A chi
square test was used to compare sociodemographic, DTC
genetic tests awareness, and numeracy characteristics across
racial/ethnic groups in Table 1. All analyses were conducted
using PASW Statistics 18.0 (formerly known as SPSS).
Results
All sociodemographic variables (age, gender, education, and
income) differed significantly across racial and ethnic cate-
gories (Table 1). Hispanic respondents were younger than
white and black respondents. Compared to white and His-
panic respondents, a greater percent of black respondents
were female. Black and Hispanic respondents had lower
educational attainment and income than white respondents.
In terms of difficulty in understanding medical statistics,
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white respondents reported the highest degree of ease, while
Hispanic respondents reported the greatest difficulty. With
regard to depending on numbers and statistics to make
health decisions, black and Hispanics respondents had sim-
ilar rates and reported “strongly agree” more often than
white respondents. In situations where the “chance of some-
thing happening” needed to be explained, white respondents
were more likely to prefer numbers whereas black and
Hispanic respondents reported a greater preference for
words. Rates of DTC genetic tests awareness were signifi-
cantly lower among black (23.8%) and Hispanic (29.7%)
respondents, than white respondents (35.1%).
Two different logistic regression models with multiple
independent variables were run using DTC genetic tests
awareness as the dependent variable. The first model includ-
ed all sociodemographic variables including race/ethnicity,
age, gender, education, and income as independent varia-
bles. As shown in Table 2, race/ethnicity was significantly
associated with DTC genetic tests awareness. Compared to
white respondents, black respondents (OR00.79; CI: 0.65–
0.97) were significantly less likely to have heard of DTC
genetic tests. In contrast, Hispanic respondents (OR01.05;
CI .85–1.29) did not significantly differ from white respond-
ents in awareness of DTC genetic tests.
Awareness of DTC genetic tests increased across strata of
income and education. However, only those in the highest
category of income ($75K or more) compared to those
making less than $19,999 were significantly more likely to
have heard of DTC genetic tests (OR01.39; CI: 1.14–1.69).
Additionally, those with the highest level of education (col-
lege) compared to respondents with less than a high school
education had significantly greater knowledge of DTC ge-
netic tests (OR02.43; CI: 1.89–3.12). Compared to 18–
Table 1 Sociodemographic, DTC genetic tests awareness, and
numeracy characteristics by racial/ethnic group (N06,754)
White Black Hispanic
Age range (%)* (n05,445) (n0687) (n0622)
18–34 11.9 18 30.2
35–49 22.7 25.8 30.3
50–64 33.2 36.8 24.7
65–74 16.8 12.5 10.8
75+ 15.4 6.9 4
Gender (% female)* 60.6 68.4 60.3
Education (%)*
< High School 6.2 15.6 27.9
High School 24.5 26.7 27.2
Some College 29.9 32.9 26.3
College 39.4 24.8 18.6
Income range (%)*
<$19,999 13.6 35.5 29.9
$20,000–34,999 15.9 20.1 22.4
$35,000–49,999 14.1 14.4 12.7
$50,000–74,999 20.2 13.6 14.4
$75,000+ 36.3 16.4 20.6
In general, how easy or hard do you find it to understand medical
statistics (%)*
Very easy 13.4 12.4 9.6
Easy 50.4 49.9 44.1
Hard 30.7 29.6 35.3
Very hard 5.6 8.1 11
In general, I depend on numbers and statistics to help me make
decisions about my health (%)*
Strongly agree 9.7 13.5 13.9
Somewhat agree 50 38.7 43.7
Somewhat disagree 26.4 24.5 23.8
Strongly disagree 13.9 23.3 18.6
When people tell you the chance of something happening, do you
prefer they use words or numbers (%)*
Generally prefer numbers 49.9 29.6 32.7
Generally prefer words 30 46.6 47.2
No preference 20.1 23.8 20.1
Have you heard or read about
genetic tests (%yes)*
35.1 26.8 29.7
*Statistically significant, p<.05
Table 2 DTC genetic tests awareness by sociodemographic correlates.
(N05,770)
Odds ratio CI
Race/ethnicity
White (reference) 1
Black* 0.79 0.65–0.97
Hispanic 1.05 0.85–1.29
Income range (%)
<$19,999 (reference) 1
$20,000–34,999 0.94 0.77–1.16
$35,000–49,999 1.02 0.82–1.26
$50,000–74,999 0.94 0.76–1.16
$75,000+ * 1.39 1.14–1.69
Gender (female) 0.99 0.88–1.12
Education (%)
< High School 1
High School 0.95 0.73–1.22
Some College* 1.35 1.05–1.73
College* 2.43 1.89–3.12
Age range (%)*
18–34 (reference) 1
35–49* 1.37 1.13–1.66
50–64* 1.75 1.46–2.1
65–74* 1.73 1.39–2.14
75+ * 1.28 1.01–1.62
*Statistically significant, p<.05
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34 year olds, those aged 50–64 (OR01.75, CI: 1.46–2.11)
had the highest odds of DTC genetic tests awareness. Lastly,
there was no difference in awareness of DTC genetic tests
by gender (OR00.99; CI: 0.88–1.12).
In our second analysis (Table 3), two of the three numer-
acy variables were added to the model. Dependence on
numbers and statistics to help make decisions about one’s
health, and preference for words or numbers when discus-
sing “the chance of something happening” were kept as
potential mediators, as they both had a relationship to black
race and DTC genetic tests awareness in Table 1. Odds
ratios for income, education, and age followed the same
trend as noted above and remained significant, however
the effect of black race (OR00.84; CI: 0.69–1.04) was no
longer significant. Gender remained non-significant in the
full model. Both numeracy variables, however, were signif-
icant predictors of DTC genetic tests awareness. Compared
to those who answered “strongly agree,” respondents who
strongly disagreed that numbers and statistics helped them
make health decisions had lower odds of DTC genetic tests
awareness (OR00.7; CI: 0.55–0.88). Compared to those
who preferred numbers, respondents who preferred words
when discussing “the chance of something happening” had
significantly lower levels of DTC genetic tests awareness
(OR00.80; CI: 0.69–0.92). We examined the interaction of
race/ethnicity with the SES and numeracy variables in
Tables 2 and 3, and found that none of these variables
moderated the association of race/ethnicity on DTC genetic
tests awareness.
Discussion
Our initial finding was that black respondents to the HINTS
survey were significantly less likely than white respondents
to have heard of DTC genetic tests, after controlling for
sociodemographics including age, gender, income and edu-
cation. This result is consistent with similar studies on
genetic testing and related behaviors (Armstrong et al.
2005; Langford et al. 2010; Suther and Kiros 2009). Our
second finding was that the association between black race
and awareness of DTC genetic tests weakened from signif-
icant to non-significant once numeracy variables were added
to the base model. While the difference in odds ratios
between the two models is small, this change suggests that
numeracy partially mediates this relationship. The finding
also suggests that the racial and ethnic disparities in DTC
genetic tests awareness are not attributed to socioeconomic
status alone, but rather to one’s preference for, and confi-
dence level with regard to numeracy.
People who strongly disagreed that they depend on
numbers and statistics to help them make health decisions
were the least likely to have heard of DTC genetic tests.
This group may be less likely to proactively seek out infor-
mation about DTC genetic tests due to limited confidence in
their ability to interpret their meaning. As such, they may
not explore medical websites or other outlets such as health
magazines where DTC or other clinical genetic tests may be
advertised. This differential exposure to health information
may contribute to more disparities in knowledge and access
to information about DTC and clinical genetic tests.
Our study also suggests the need for further research on
the impact of numeracy on DTC genetic test awareness,
utilization, and medical decision making based on results.
The format in which numbers and risk information is pre-
sented to consumers warrants more attention. Although
Table 3 DTC genetic tests awareness by sociodemographic and
numeracy correlates. (N05,678)
Odds ratio CI
Race/ethnicity
White (reference) 1
Black 0.84 0.69–1.04
Hispanic 1.05 0.85–1.3
Income range (%)
<$19,999 (reference) 1
$20,000–34,999 0.94 0.77–1.17
$35,000–49,999 1.0 0.80–1.23
$50,000–74,999 0.92 0.75–1.14
$75,000+ * 1.33 1.1–1.63
Gender (female) 1.03 0.92–1.17
Education
< High School 1
High School 0.95 0.74–1.24
Some College 1.33 1.03–1.72
College* 2.29 1.76–2.96
Age range
18–34 (reference) 1
35–49* 1.37 1.13–1.67
50–64* 1.75 1.46–2.11
65–74* 1.78 1.43–2.22
75+ * 1.35 1.06–1.73
In general, I depend on numbers and statistics to help me make
decisions about my health.
Strongly agree (reference) 1
Somewhat agree 0.90 0.74–1.09
Somewhat disagree* 0.72 0.59–0.89
Strongly disagree* 0.70 0.55–0.88
When people tell you the chance of something happening, do you
prefer they use words or numbers?
Generally prefer numbers (reference) 1
Generally prefer words* 0.8 0.69–0.92
No preference 0.93 0.8–1.08
*Statistically Significant, p<.05
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many studies have examined the link between numeracy and
various types of risk communication, there is no consensus
in the field on the “best” way to present health information.
For example, probabilities, risk comparisons, graphical dis-
plays, ratios, and qualitative explanations have all been used
to present risk information (Akl et al. 2011; Lipkus 2007;
Fischhoff et al. 2011; Leighton et al. 2011). Given that
numeracy levels in the U.S. are generally low and that great
variation exists among consumers with regard to preferences
for risk information (Reyna et al. 2009), a variety of tools
are needed to ensure that people can use numbers in a way
that facilitates informed medical decisions. One emerging
strategy is to tailor format and content to individual needs
and preferences (Kreuter et al. 1999). Additionally, simple
to administer numeracy scales already exist and can poten-
tially be used to facilitate tailoring on numeracy (Fagerlin et
al. 2007).
Practice Implications
Based on our findings, we propose that numeracy may be a
barrier to access and knowledge of useful genetic informa-
tion among black consumers. More research, including both
qualitative and quantitative, is needed to understand how
black consumers perceive, access, and utilize DTC genetic
tests. This holds true for Hispanic consumers as well. In-
creased community engagement may inform which strate-
gies are most helpful to diverse populations for evaluating
the benefits and drawbacks of DTC genetic tests. For exam-
ple, online education modules, webinars, community
forums, advocacy groups, newsletters, and social media
are being used by the GenoCommunity Think Tank, the
Genetic Alliance, and other groups to educate the public
about genomics (GenoCommunity Think Tank 2011; Ge-
netic Alliance 2011).
Although Hispanic respondents in our study did not
differ significantly from white respondents in DTC genetic
tests awareness, little is known about Hispanic consumers
with regard to genetic tests. A study done with a Puerto
Rican sample found that the majority of respondents (56%)
were aware of DTC genetic tests (Ortiz et al. 2011). In
contrast, another study found that Hispanics had low aware-
ness of clinical genetic tests for breast cancer, despite report-
ing a desire to receive more information about hereditary
cancer and genetic testing (Ramirez et al. 2006). A better
understanding of how, if at all, DTC genetic companies
advertise to Hispanic audiences warrants more attention,
especially pertaining to availability of Spanish language
and other culturally appropriate materials.
Given the growing number of users of DTC genetic tests,
genetic counselors and primary care physicians may see
increases in questions and concerns from patients. To ac-
commodate the diversity in numeracy skill, preference, and
comfort among consumers, these clinicians may benefit
from training on how to tailor communications of risk
information. Screening tools that assess patient preferences
for health information may also be helpful (e.g. numbers,
words, or graphs), although it is not clear that patients know
what formats they actually understand best.
Finally, alternative ways of conveying numbers warrants
more attention. For example, pictographs, used to make
risk-related statistics easier to interpret, and social math
involving relation of information to things people already
understand (e.g. number of people who can fit into a 747
airplane or school bus) may be useful tools for explaining
risk information to low numerate consumers (CDC 2008;
Garcia-Retamero and Galesic 2010; Zikmund-Fisher et al.
2010; Center for Health Improvement 2004). It may also be
useful to assess the effectiveness of combining numerical
data with qualitative explanations when reporting results of
DTC and clinical genetic tests.
Study Limitations
Limitations include our inability to explore the full domain
of numeracy, as two of the five items in HINTS 2007 were
excluded because they were only asked in one format of the
survey (phone or mail). Measuring race is complex (Kaplan
and Bennett 2003). Since broad racial and ethnic categories
were used and no multiracial classification was evaluated,
we cannot account for within group differences among
white, black, and Hispanic respondents. This limits the
precision and generalizability of our inferences. It should
also be noted that achieving statistical significance in a large
sample does not necessarily imply clinical significance.
Finally, trends in DTC genetic tests awareness and numer-
acy over time could not be evaluated as these questions were
asked in the HINTS 2007 survey, prior to mainstream media
coverage of genetic testing that has occurred in recent years.
For example, in 2008, the Genetic Information Nondiscrim-
ination Act was passed (110th Congress 2008) and Time
magazine named “The Retail DNATest” its Invention of the
Year (Hamilton 2008).
Conclusion
To our knowledge, this is the first study to directly examine
the role of numeracy on DTC genetics test awareness. Our
findings show that among black, white, and Hispanic
respondents to the HINTS 2007 survey, racial and ethnic
disparities exist with regard to DTC genetic tests awareness.
However, these disparities are no longer significant once
accounting for respondents’ numeracy, suggesting that nu-
meracy may partially explain an individual’s willingness to
seek out and pay attention to DTC genetic tests. Given the
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implications for health decisions based on DTC genetic test
results, more research is needed to better understand the
relationship between numeracy and DTC genetic testing.
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